- Home
- PCF vs NTHI Comparison
PCF vs NTHI Comparison
Compare PCF & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCF | NTHI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.3M | 114.6M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCF | NTHI |
|---|---|---|
| Price | $5.39 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 64.7K | ★ 88.7K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.36 | $3.01 |
| 52 Week High | $6.51 | $12.99 |
Technical Indicators
Market Signals| Indicator | PCF | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 29.70 |
| Support Level | $5.38 | N/A |
| Resistance Level | $5.66 | $5.78 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 10.70 | 17.35 |
Price Performance
Historical ComparisonAbout PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.